Mr. Philippe Dubuc reports

THERATECHNOLOGIES ANNOUNCES AVAILABILITY OF EGRIFTA WR™ (TESAMORELIN) FOR INJECTION TO REDUCE EXCESS ABDOMINAL FAT IN ADULTS WITH HIV AND LIPODYSTROPHY

Theratechnologies Inc. has noted the availability of Egrifta WR (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of Egrifta WR by the United States Food and Drug Administration (FDA) earlier this year.

"Excess visceral abdominal fat is an increasingly important health concern for people living with HIV, and for the health care providers who treat them," said Christian Marsolais, PhD, senior vice-president and chief medical officer at Theratechnologies. "With Egrifta WR, we aim to simplify the management of excess visceral abdominal fat and enhance users' experience, as part of our commitment to helping people with HIV live their best lives."

The new, improved formulation of tesamorelin for injection -- the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy -- will gradually replace Egrifta SV, the current formulation. Specialty pharmacies are now ordering Egrifta WR to fill prescriptions for the new formulation. Egrifta SV will continue to be available during a transitional period as managed care plans increasingly provide coverage for Egrifta WR.

Egrifta WR only needs weekly reconstitution and requires less than half the injection volume as Egrifta SV, which is reconstituted daily. The product is supplied as four single-patient-use vials, each containing 11.6 milligrams of tesamorelin, sufficient for seven daily injections. The daily dose is 1.28 mg (0.16 mL (millilitre) of the reconstituted solution) injected subcutaneously. Egrifta WR can be stored at room temperature (20 degrees to 25 degrees Celsius (68 degrees to 77 degrees Fahrenheit)) before and after reconstitution. The Egrifta WR formulation is patent protected in the U.S. until 2033.

Pharmacokinetic studies have shown bioequivalence of Egrifta WR to the original F1 formulation of tesamorelin for injection (previously sold under the trade name Egrifta). The most commonly reported adverse reactions of tesamorelin for injection include arthralgia, injection site reactions, pain in extremity, peripheral edema and myalgia.

Individuals with HIV and lipodystrophy who are currently using Egrifta SV can enroll in the Thera patient support program to help them transition to Egrifta WR as insurance coverage becomes available. The program, which is offered free of charge, includes a dedicated team of Thera Nurse Navigators who are available to train enrolled patients on the use of Egrifta WR.

"Our goal is to ensure a smooth transition to Egrifta WR for all eligible patients, and to safeguard their ongoing care," Dr. Marsolais commented.

About Theratechnologies Inc.

Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care.

We seek Safe Harbor.